The global Alzheimer’s diagnostics and therapeutics market is projected to witness significant growth in the coming decade, reaching an estimated valuation of USD 14.8 billion by 2033. According to a recent study by Future Market Insights, the market is expected to grow from USD 6.6 billion in 2023, registering a robust compound annual growth rate (CAGR) of 8.4% over the forecast period.
In 2022, the diagnostics segment led the market, commanding a share of approximately 54.1% within the global Alzheimer’s diagnostics and therapeutics landscape. This dominance highlights the increasing importance of early and accurate diagnosis in the management of Alzheimer’s disease, which remains a critical challenge in the healthcare sector.
The anticipated growth is driven by advancements in diagnostic technologies, an aging global population, and an increasing focus on early intervention and personalized treatment strategies. As research continues to evolve and innovative therapies emerge, the market is expected to see substantial developments that will enhance patient outcomes and improve quality of life for those affected by Alzheimer’s.
Many new technologies are being used to monitor Alzheimer’s disease and to detect its progression over time, which guides individuals in maintaining and tracking their activities. Much new research has emerged which investigates cloud-based solutions to dementia and Alzheimer’s disease, including care, treatment, and diagnosis. There are several drugs in the pipeline for the treatment of Alzheimer’s disease, which is expected to receive regulatory approvals in the coming years. For instance, Biogen’s Aducanumab received FDA approval in 2021, making it the first new drug for Alzheimer’s disease in almost 20 years. Such pipeline developments could drive the growth of the Alzheimer’s therapeutics market.
Advancements in imaging technologies such as positron emission tomography (PET) and magnetic resonance imaging (MRI) have allowed for improved detection of structural and functional changes in the brain associated with Alzheimer’s disease. Several new drug therapies have emerged in recent years, including monoclonal antibodies that target beta-amyloid and tau proteins. These drugs have shown promise in slowing or halting the progression of the disease. Gene therapy is a promising approach to treating Alzheimer’s disease by delivering therapeutic genes to affected areas of the brain. While still in the experimental stages, this approach has shown potential in preclinical studies.
Overall, these advancements in diagnostics and therapeutics are helping to improve the understanding of Alzheimer’s disease and develop more effective treatments for this devastating condition.
Moreover, the Alzheimer’s diagnostics and therapeutics market is expected to grow in the coming years due to the increasing aging population, advancements in diagnostics and therapeutics, pipeline developments, rising healthcare spending, and technological advancements.
Key Takeaways from Market Study:
- Diagnostics is the leading segment by product, and held a 1%market value share in 2022, owing to new technologies that are being used to monitor Alzheimer’s disease and to detect its progression.
- By distribution channel, institutional sales are leading in the global Alzheimer’s diagnostics and therapeutics market, and are expected to continue to do so with a projected CAGR of 3%during the forecasted years.
- North America is considered the leading region with a value share of 0%in 2022, as there is a growing number of people in the U.S. who are at risk of developing Alzheimer’s disease.
Market Competition:
Eisai Inc., AlzeCure Pharma, TrueBinding, Inc., and Cognition Therapeutics are some of the key players who are involved in the clinical trials, among others in the study of Alzheimer’s diagnostics and therapeutics. Many companies strategize to acquire any competitor or company that generates less revenue. The business alliance aims to support the distribution of the product portfolio across developed regions and emerging players are focusing on expanding to strengthen their product portfolio.
- In March 2022, AbbVie acquired Syndesi Therapeutics to expand its Neuroscience Portfolio.
- In February 2022, Janssen and partnered company AC Immune found that at an early stage, the Alzheimer’s vaccine activates the induction of antibodies that attacks tau, a type of protein.
Key Market Segments Covered in Alzheimer’s diagnostics and therapeutics Industry Research
By Product:
- Therapeutics
- Cholinesterase Inhibitors
- NMDA Receptor Antagonists
- Manufactured Combination
- Diagnostics
- Lumbar Diagnostics Test
- CT Scan
- MRI
- EEG
- PET scan
By Distribution Channel:
- Institutional Sales
- Hospitals
- Specialty Clinics
- Diagnostic Centers
- Retail Sales
- Retail Pharmacies
- Drug Stores
- Online Pharmacies
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa (MEA)
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
